化疗诱发的周围神经病变（CIPN）是直接因接受癌症治疗而导致的一种使人虚弱的病症。CIPN的分子病因尚不清楚，有理论认为可能存在遗传因素。谷胱甘肽-S-转移酶（GST）基因中的遗传多态性，包括GSTM1、GSTT1和GSTP1，编码用于代谢化疗药物的酶，已被认为可能与CIPN有关。本研究旨在调查这些基因中的四个标记与CIPN（n = 172）在混合癌症群体中的关联。使用患者报告的不良反应常用术语评估（PRO-CTCAE）评估中的神经病项来测量CIPN。所有样品的基因分型均使用PCR检测GSTM1和GSTT1零变异体和使用限制性片段长度多态性检测GSTM1和GSTM1多态性。在我们的研究中，没有发现GST基因标记与CIPN或CIPN严重程度之间的关联。将CIPN表型纵向分层以检查神经病的关联，发现GSTM * null等位基因（p值= 0.038，OR = 0.55）和治疗第2个月时疼痛的存在具有名义上的显著保护性关联，而对于GSTM1* null等位基因的个体，GSTT1 * null等位基因则是治疗第2个月疼痛相关的风险因素（p值= 0.030，OR = 1.64）。与没有CIPN的患者相比，CIPN患者的疼痛严重程度在每个时间点上持续较高。没有发现CIPN与GSTM1，GSTT1和GSTP1的多态性之间的关联。然而，发现GSTM1-null和GSTT1-null多态性与化疗后第2个月的疼痛相关的关联。©2023作者。

Chemotherapy induced peripheral neuropathy (CIPN) is a debilitating condition that is a direct consequence of receiving cancer treatment. The molecular aetiology of CIPN is not well understood, and it is theorised that there may be a genetic component. Genetic polymorphisms in Glutathione-S Transferase (GST) genes, including GSTT1, GSTM1 and GSTP1, encode for enzymes known to metabolise drugs used in chemotherapy, and have been theorised to be associated with CIPN. This study aimed to investigate four markers in these genes for an association in a mixed cancer cohort in relation to CIPN (n = 172).CIPN was measured using the neuropathy item from the Patient Reported Outcome Common Terminology Criteria for Adverse Event (PRO-CTCAE) assessment. Genotyping for all samples was performed using PCR for the GSTM1 and GSTT1 null variants and restriction fragment length polymorphisms for the GSTP1 and GSTM1 polymorphisms.No associations were found for the GST gene markers in relation to CIPN within our study, or CIPN severity. Longitudinal stratification of the CIPN phenotypes to examine links for neuropathy, identified nominally significant protective associations with the GSTM* null allele (p-value = 0.038, OR = 0.55) and the presence of pain at month 2 of treatment, as well as a risk factor for pain related month 2 of treatment for individuals with the GSTT1*null allele (p-value = 0.030, OR = 1.64). Higher severity of pain in patients with CIPN persisted at each time-point compared to those without CIPN.No significant results for an association between CIPN with polymorphisms in GSTM1, GSTT1 and GSTP1 were identified. However, associations for the GSTM1¬-null and GSTT1-null polymorphisms with pain at month 2 following chemotherapy were identified.© 2023. The Author(s).